Whole Shine Medical Technology Co (002622) Fair Value & Analysis
Industrials · CN · Market cap 1.9B CNY
Fair value as of: Jun 25, 2026
Analysis
Whole Shine Medical Technology Co (002622) currently trades at ¥2.26, while our model-based Fair Value estimate is ¥0.6200 — implying the stock looks roughly 72.6% overvalued today. We read business quality at 91/100 (high quality), in the Industrials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
Whole Shine Medical Technology Co., Ltd. engages in the oral medical services business in China. The company is also involved in the research and development, production, and sale of permanent magnet switches and high and low voltage switch complete sets of equipment products; provision of high-voltage switchgears, low voltage switchgear of other models, permanent magnet indoor high voltage vacuum breaker, circuit breakers, as well as permanent magnet high voltage vacuum circuit breakers for arc furnaces and contactors, switch state controllers, and outdoor box-type substations. In addition, it offers diagnosis and treatment of oral diseases, oral health care and restoration services; accepts deposits; grants loans; and banking business. The company was formerly known as Rongyu Group Co.,Ltd. and changed its name to Whole Shine Medical Technology Co., Ltd. in December 2022. Whole Shine Medical Technology Co., Ltd. was founded in 1986 and is based in Beijing, China.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Whole Shine Medical Technology Co (002622) undervalued?
What is the fair value of 002622?
What is the quality score of 002622?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.